Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K.
Gallagher DJ, et al.
Clin Cancer Res. 2010 Apr 1;16(7):2115-21. doi: 10.1158/1078-0432.CCR-09-2871. Epub 2010 Mar 9.
Clin Cancer Res. 2010.
PMID: 20215531
Free PMC article.